Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Cantor Fitzgerald
Argus Health
McKinsey
Dow
Colorcon
Queensland Health
Chinese Patent Office
Deloitte

Generated: August 18, 2018

DrugPatentWatch Database Preview

REXULTI Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Rexulti, and when can generic versions of Rexulti launch?

Rexulti is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. There are four patents protecting this drug.

This drug has twenty-nine patent family members in twenty-five countries.

The generic ingredient in REXULTI is brexpiprazole. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the brexpiprazole profile page.

Summary for REXULTI
Drug patent expirations by year for REXULTI
Generic Entry Opportunity Date for REXULTI
Generic Entry Date for REXULTI*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for REXULTI
Synonyms for REXULTI
2(1H)-Quinolinone, 7-(4-(4-benzo(b)thien-4-yl-1-piperazinyl)butoxy)-
2J3YBM1K8C
7-(4-(4-(1-Benzothiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
7-(4-(4-(Benzo[b]thiophen-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one
7-[4-(4-benzo[b]thien-4-yl-1-piperazinyl)butoxy]- 2(1H)-Quinolinone
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)-butoxy]-1H-quinolin-2-one
7-[4-(4-benzo[b]thiophen-4-yl-piperazin-1-yl)butoxy]-1H-quinolin-2-one
7-[4-(4-Benzo[b]thiophen-4-ylpiperazin-1-yl)butoxy]-1H-quinolin-2-one
7-[4-[4-(1-benzothiophen-4-yl)piperazin-1-yl]butoxy]-1H-quinolin-2-one
913611-97-9
AK171366
AKOS025291100
AX8306230
BC600277
BREXPIPRAZOLE
Brexpiprazole (JAN/USAN/INN)
Brexpiprazole [USAN:INN]
Brexpiprazole(OPC34712)
CHEBI:134716
CHEMBL2105760
CS-2108
D0P0OU
D10309
DB09128
DTXSID40238527
FT-0712292
GTPL7672
HY-15780
KS-0000063N
MFCD27987920
MolPort-039-063-477
MolPort-046-033-502
OPC 34712
OPC-34712
OPC34712
Rexulti (TN)
s4639
SCHEMBL1037592
SCHEMBL14772509
UNII-2J3YBM1K8C
ZINC84758479
ZKIAIYBUSXZPLP-UHFFFAOYSA-N

US Patents and Regulatory Information for REXULTI

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-006 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-005 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-001 Jul 10, 2015 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Otsuka Pharm Co Ltd REXULTI brexpiprazole TABLET;ORAL 205422-004 Jul 10, 2015 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Non-Orange Book US Patents for REXULTI

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,206,167 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
9,480,686 Piperazine-substituted benzothiophenes for treatment of mental disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Baxter
US Army
Cantor Fitzgerald
Dow
Queensland Health
Farmers Insurance
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.